The B.E. Journal of Economic Analysis & Policy
Editor-in-Chief: Jürges, Hendrik / Ludwig, Sandra
Ed. by Auriol , Emmanuelle / Brunner, Johann / Fleck, Robert / Friebel, Guido / Mendola, Mariapia / Requate, Till / Tsui, Kevin / Wichardt, Philipp / Zulehner, Christine
4 Issues per year
IMPACT FACTOR 2013: 0.432
5-year IMPACT FACTOR: 0.710
SCImago Journal Rank (SJR): 0.956
Source Normalized Impact per Paper (SNIP): 0.734
Volume 14 (2014)
Volume 12 (2012)
Volume 11 (2011)
Volume 9 (2009)
Volume 6 (2006)
Volume 4 (2004)
Volume 2 (2002)
Volume 1 (2001)
Most Downloaded Articles
- The Inheritance of Educational Inequality: International Comparisons and Fifty-Year Trends by Hertz, Tom/ Jayasundera, Tamara/ Piraino, Patrizio/ Selcuk, Sibel/ Smith, Nicole and Verashchagina, Alina
- IQ and Family Background: Are Associations Strong or Weak? by Björklund, Anders/ Hederos Eriksson, Karin and Jäntti, Markus
- Do Rising Top Income Shares Affect the Incomes or Earnings of Low and Middle-Income Families? by Thompson, Jeffrey P. and Leight, Elias
- Therapeutic Equivalence and the Generic Competition Paradox by Nabin, Munirul Haque/ Mohan, Vijay/ Nicholas, Aaron and Sgro, Pasquale M.
- Before and After: Gender Transitions, Human Capital, and Workplace Experiences by Schilt, Kristen and Wiswall, Matthew
In Whom We Trust: The Role of Certification Agencies in Online Drug Markets
1Department of Economics, American Enterprise Institute, Washington, DC, USA
2Department of Economics, University of Maryland, College Park, MD, USA
3American Enterprise Institute, 1150 Seventeenth Street, Washington, DC 20036, USA
Citation Information: The B.E. Journal of Economic Analysis & Policy. Volume 14, Issue 1, Pages 111–150, ISSN (Online) 1935-1682, ISSN (Print) 2194-6108, DOI: 10.1515/bejeap-2013-0085, December 2013
- Published Online:
This article uses an audit sample and a consumer survey to study the intriguing market of online prescription drugs facing US customers and assesses the role that certification agencies play in online drug markets.
On the supply side, we acquire samples of five popular brand-name prescription drugs from three types of online pharmacies: tier 1 are US-based and certified by the National Association of Boards of Pharmacy (NABP) or LegitScript.com, tier 2 are certified by PharmacyChecker.com or the Canadian International Pharmacy Association but not by NABP or LegitScript, and tier 3 are not certified by any of the four agencies. Most tier-2 and tier-3 websites are foreign. We find that 37 of the 365 delivered samples are different from the products we ordered and, therefore, non-testable. Conditional on testable samples, Raman spectrometry test finds no failure of authenticity except for eight Viagra samples from tier-3 websites. After controlling for testability and authenticity, tier-2 websites are 49.2% cheaper (p<0.01) and tier-3 websites are 54.8% cheaper (p < 0.01) than tier-1 sites. These differences are driven by non-Viagra drugs. For Viagra, failing samples are cheaper, but there is no significant price difference across tiers once we condition on testability and authenticity.
To study the demand side, we designed a survey that was distributed by RxRights. Among the 2,522 respondents who have purchased prescription medication and are concerned about the price of US pharmaceuticals, results show that 61.54% purchase drugs online and mostly from foreign websites, citing cost saving as the leading reason. Conditional on shopping online, 41.11% check with a credentialing agency.
Both samples convey a consistent message that certification agencies deliver useful information for foreign websites and online consumers. Further, while these findings confirm the Food and Drug Administration warning against rogue websites, they do suggest that a blanket ban against all foreign websites may deny consumers substantial savings from certified tier-2 websites.